2-(4-氯苯氧基)吡啶-3-羰酰氯 | 51362-50-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(4-氯苯氧基)吡啶-3-羰酰氯
• 英文名称: 2-(4-chlorophenoxy)nicotinoyl chloride
• 英文别名: 2-(4-Chlorophenoxy)pyridine-3-carbonyl chloride
• CAS: 51362-50-6
• 化学式: C₁₂H₇Cl₂NO₂
• mdl: MFCD00067837
• 分子量: 268.099
• InChiKey: CAEKTJMKOZHNPM-UHFFFAOYSA-N

物化性质

• 熔点：
  79 °C
• 沸点：
  369.7±32.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2933399090
• 危险品运输编号：
  UN 3261

SDS

Name:	2-(4-Chlorophenoxy)pyridine-3-carbonyl chloride 95+% Material Safety Data Sheet
Synonym:	None Known
CAS:	51362-50-6

Section 1 - Chemical Product MSDS Name:2-(4-Chlorophenoxy)pyridine-3-carbonyl chloride 95+% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
51362-50-6	2-(4-Chlorophenoxy)pyridine-3-carbonyl	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid immediately.
Skin:
In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical aid immediately. Wash clothing before reuse.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing.
Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store protected from moisture. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 51362-50-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H7Cl2NO2
Molecular Weight: 268

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures. Moisture sensitive.
Conditions to Avoid:
Incompatible materials, dust generation, exposure to moist air or water.
Incompatibilities with Other Materials:
Oxidizing agents, bases, alcohols, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 51362-50-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(4-Chlorophenoxy)pyridine-3-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 51362-50-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 51362-50-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 51362-50-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-氯苯氧基)吡啶-3-羰酰氯 在 吡啶 、 lithium hydroxide 、 正丁基锂 、 甲基锂 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 hexanes 、 二氯甲烷 为溶剂， 反应 0.75h， 生成 N-[(1S)-1-[4-[2-(4-chlorophenoxy)pyridine-3-carbonyl]phenyl]ethyl]methanesulfonamide
  参考文献：
  名称：

  [EN] CANNABINOID RECEPTOR AGONISTS
  [FR] AGONISTES DU RECEPTEUR CANNABINOIDE

  摘要：

  式(I)的化合物或其药学上可接受的盐，其中：R1、R2、R3、R4、R5、R6、L1、L2、M、n、p、X、Y和Z如说明书中所述；其药物组合物，制备该药物组合物的方法；以及使用该药物的方法。

  公开号：

  WO2004000807A1
• 作为产物：
  描述：

  2-(4-氯苯氧基)烟酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-(4-氯苯氧基)吡啶-3-羰酰氯
  参考文献：
  名称：

  含有快速降解四氢邻苯二甲酰亚胺的新型二苯醚衍生物的设计，合成和除草活性。

  摘要：

  为了寻找具有更好生物活性的新型原卟啉原氧化酶（PPO）抑制剂，基于亚结构剪接和生物异构化的原理，设计了一系列新型的含有四氢邻苯二甲酰亚胺的二苯醚衍生物。PPO抑制实验显示6c是最有潜力的化合物，其半数最大抑制浓度（IC50）值为0.00667 mg / L，显示出比抗氧氟芬（IC50 = 0.0426 mg / L）高7倍的抗玉米PPO活性和类似的除草活性在温室除草实验和田间除草实验中使用Oxyfluorfen。鉴于所检查的生物活性，还讨论了该系列化合物的结构-活性关系（SAR）。作物选择实验表明，化合物6c对于大豆，玉米，大米，花生和棉花的剂量为300 g ai / ha。积累分析实验表明，某些作物（大豆，花生和棉花）中6c的积累显着低于Oxyfluorfen。当前的工作表明化合物6c可以作为田间除草剂的新候选物开发。

  DOI：

  10.1021/acs.jafc.0c00947

文献信息

• Phenyl heterocyclyl ethers
  申请人：——

  公开号：US20030207857A1

  公开（公告）日：2003-11-06

  The invention relates to compounds of formula I 1

  该发明涉及公式I1的化合物。
• Novel compounds and their use in therapy
  申请人：Hirvelae Leena

  公开号：US20050176742A1

  公开（公告）日：2005-08-11

  Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17β-hydroxysteroid dehydrogenase enzymes.

  硫代嘧啶酮化合物及其在治疗中的应用，特别是用于治疗和/或预防类固醇激素依赖性疾病或紊乱，如需要抑制17β-羟基类固醇脱氢酶酶的类固醇激素依赖性疾病或紊乱。
• [EN] SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF<br/>[FR] PIPERIDINES SPIROCYCLIQUES UTILISEES COMME ANTAGONISTES DES MCH1 ET UTILISATIONS ASSOCIEES
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2004004714A1

  公开（公告）日：2004-01-15

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

  这项发明涉及选择性拮抗黑色素浓缩激素-1（MCH1）受体的化合物。该发明提供了一种药物组合物，包括本发明的化合物的治疗有效量和药学上可接受的载体。该发明提供了一种通过结合本发明的化合物的治疗有效量和药学上可接受的载体制备的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明的化合物的治疗有效量和药学上可接受的载体。该发明还提供了一种减少受试者体重的方法，包括向受试者投与本发明化合物的有效量以减少受试者体重。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者投与本发明化合物的有效量以治疗受试者的抑郁症和/或焦虑症。该发明还提供了一种治疗患有尿液失调的受试者的方法。
• [EN] PHENYL HETEROCYCLYL ETHER DERIVATIVES AS SEROTONIN RE-UPTAKE INHIBITORS<br/>[FR] DERIVES DE PHENYLE HETEROCYCLYLE ETHER UTILISES COMME INHIBITEURS DU RECAPTAGE DE LA SEROTONINE
  申请人：PFIZER LTD

  公开号：WO2002083643A1

  公开（公告）日：2002-10-24

  The invention relates to compounds of the formula (I) which exhibit activity as selective serotonin re-uptake inhibitors.

  本发明涉及公式（I）的化合物，其表现出作为选择性血清素再摄取抑制剂的活性。
• Novel aromatic compounds
  申请人：——

  公开号：US20030186944A1

  公开（公告）日：2003-10-02

  Disclosed are compounds of formula I 1 wherein A, R1, R2, R3, R4 and R5 are described in the specification, pharmaceutical formulations comprising these compounds, the use of these compounds as medicaments, the use of these medicaments in the treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (NIDDM or Type 2 diabetes), as well as methods for treating diabetes comprising administration of these compounds.

  本发明揭示了式I1化合物，其中A、R1、R2、R3、R4和R5如规范中所述，以及包含这些化合物的药物制剂，这些化合物作为药物的用途，这些药物用于治疗和/或预防糖尿病，特别是非胰岛素依赖性糖尿病（NIDDM或2型糖尿病），以及包括这些化合物的给药方法来治疗糖尿病。